<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00545077</url>
  </required_header>
  <id_info>
    <org_study_id>GEICAM/2006-11/GBG 51</org_study_id>
    <secondary_id>Nº EudraCT: 2007-002841-19</secondary_id>
    <nct_id>NCT00545077</nct_id>
  </id_info>
  <brief_title>Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line Treatment in Postmenopausal Patients With Advanced or Metastatic Breast Cancer</brief_title>
  <official_title>Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Bevacizumab in Combination With Endocrine Treatment Compared to Endocrine Treatment Alone, in Postmenopausal Women With Advanced or Metastatic Cancer With Indication of Hormonotherapy as First-line Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Breast Cancer Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>German Breast Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Spanish Breast Cancer Research Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Locally advanced or metastatic breast cancer in postmenopausal women with negative HER2, who
      are candidates for hormone treatment and who have not received previous chemotherapy or
      hormonotherapy for the metastatic disease.

      The main endpoint of the study is PFS. It has been calculated that 378 patients will need to
      be included, according to the following assumptions:

        -  Recruitment period of 21 months.

        -  Minimum follow-up period of 9 months.

        -  PFS of 9 months in the control arm (letrozole in monotherapy). Using a two-sided
           log-rank test, for a 5% α level, 344 patients (172 in each treatment arm) will be
           required for 270 events to occur, which will provide an 80% power for detecting a hazard
           ratio of 0.69 (corresponding to a PFS median of 13 months in the bevacizumab arm). This
           sample size has been adjusted for an intermediate analysis when 2/3 of the total of
           required events have occurred. This intermediate analysis can be avoided if, at the time
           in which it must be carried out, it is estimated that the final analysis will be carried
           out in 4 months.

      Taking into account a 10% percentage of losses, 378 patients are expected to be included in
      the study.

      An intermediate safety evaluation will be carried out when 63 patients have finished their
      treatment in each treatment arm.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multicenter, randomized phase III clinical trial. After verifying the selection criteria,
      the patients will be randomized to receive letrozole alone or in combination with
      bevacizumab. Before randomization, the patients will be stratified according to the following
      prognosis factors:

        -  ER+/PgR+ vs the other options (ER+/PgR- vs ER-/PgR+)

        -  Previous adjuvant hormonotherapy (yes/no)

        -  Status: locally advanced vs metastatic.

        -  Measurable vs non measurable disease

        -  Visceral disease (yes/no)

        -  PFS.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>·To compare the progression-free survival (PFS) between both treatment arms.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>· Overall survival (OS) · Time to treatment failure (TTF) · Better response to treatment (RR) · Response duration (RD) · Clinical benefit proportion (CBP = CR + PR + SD &gt; 6 months) · Safety and tolerance</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">378</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>• Endocrine treatment consisting of either letrozole or fulvestrant.The patients will be randomized to receive bevacizumab 15mg/kg every 3 weeks plus endocrine treatment or endocrine treatment as a single agent. The patients will receive the assigned treatment until the progression of the disease, unacceptable toxicity or withdrawal of the consent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bevacizumab: 15 mg/Kg i.v. on day 1 every 3 weeks plus Endocrine treatment consisting of either letrozole or fulvestrant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Endocrine treatment consisting of either letrozole or fulvestrant.</intervention_name>
    <description>The patients will receive the assigned treatment until the progression of the disease, unacceptable toxicity or withdrawal of the consent.</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab + Endocrine treatment consisting of either letrozole or fulvestrant.</intervention_name>
    <description>Bevacizumab will be administered every 21 days (day 1 of cycle 2 will be day 22 of the treatment.The patients will receive the assigned treatment until the progression of the disease, unacceptable toxicity or withdrawal of the consent. Those patients in treatment with bevacizumab who end the study without having progressed will continue to receive the drug out of the study.</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Before starting the specific protocol procedures, the written informed consent must be
             obtained and documented.

          2. Women ≥ 18 years.

          3. Capacity to comply with all the protocol requirements.

          4. Functional ECOG status of 0 or 1.

          5. Life expectancy ≥ 24 weeks.

          6. Histologically confirmed breast adenocarcinoma, with measurable or non-measurable,
             locally advanced or metastatic (stage IV) disease. In the event that the patient only
             has locally advanced disease, she will not be able to undergo curative local
             treatment. Patients with metastasis confined to the bone can be chosen, but the
             disease must be confirmed by radiology, CT scan or NMR if there is any doubt after a
             single bone scan.

          7. Patients with HER2-negative disease evaluated by IHC and FISH/CISH (IHC 0 or 1+, or 2+
             and negative FISH). Patients with 3+ by IHC cannot be chosen regardless of the
             FISH/CISH status and those with positive FISH/CISH (&gt; 2 amplifications) cannot be
             chosen either, regardless of the IHC findings.

          8. Positive hormone receptors (estrogen receptor [ER] and/or progesterone receptor [PgR])
             evaluated by a local or central laboratory, according to the criteria of the
             participating institution.

          9. Patients who are candidates for receiving first-line treatment with letrozole.

         10. Patients may have received (neo)adjuvant chemotherapy, provided that the last dose of
             the latter was received at least 12 months before randomization . Patients must be
             recovered from toxicity.

         11. The patients are allowed to have received adjuvant radiotherapy, provided that it was
             completed at least 6 weeks before randomization and the patient has recovered from the
             reversible acute effects of the radiation. The previous administration of radiotherapy
             to palliate the pain of bone metastases is authorized, provided that:

               -  Not more than 30% of bone marrow has been irradiated.

               -  The patient has recovered from the reversible acute effects of the radiation.

               -  The patient has at least one metastatic location which has not been irradiated
                  and which may be evaluated for progression, or a clear progression of the bone
                  disease has been objectified after the end of the palliative radiotherapy.

         12. The patients may have received any kind of previous (neo)adjuvant hormone therapy
             provided that they are considered to be candidates for first-line hormonotherapy with
             either letrozole or fulvestrant.

         13. The treatment with bisphosphonates is allowed and recommended for patients with bone
             metastases. Whenever it is possible, the treatment should be started before or within
             the 4 weeks of starting the study therapy. The patients starting treatment with
             bisphosphonates must be carefully evaluated so that they do not mask the progression
             of the disease.

         14. In the patients with heart failure risk (e.g. previously treated with &gt; 360mg/m2 of
             doxorubicin or equivalent doses of other anthracyclines), the LVEF must be determined
             by means of an echocardiogram or radionuclide ventriculography (MUGA), and it must t
             be &gt; the lower limit of normal.

        Exclusion Criteria:

          1. Evolutionary disease requiring an immediate treatment with cytotoxic chemotherapy
             according to the investigator's judgment.

          2. Patients with locally advanced breast cancer who are expected to undergo surgery or
             curative radiotherapy.

          3. Previous chemotherapy or hormonotherapy for the metastatic disease. Patients may have
             received neoadjuvant chemotherapy or neoadjuvant hormonotherapy with curative
             intention as a part or as an alternative to an adjuvant treatment. For the previous
             neoadjuvant hormonotherapy the same premises than for the adjuvant hormonotherapy are
             valid.

          4. Previous therapy with anti-VEGF or VEGFR tyrosine-kinase inhibitors.

          5. History of another pathology that may affect the development of the protocol or the
             interpretation of results. It is considered that patients who have suffered from a
             skin carcinoma that is not melanoma, cervical carcinoma in situ or another neoplasia
             treated with a curative intention and with a disease-free interval exceeding 5 years
             can be chosen.

          6. Evidence of CNS metastasis. A CT scan or brain NMR must be done within the 4 weeks
             before the randomization in case of suspecting brain metastasis.

          7. History or evidence in the physical or neurological examination of CNS pathology
             unrelated to cancer unless it is suitable treated with standard therapy (e.g.
             uncontrolled convulsions).

          8. History of peripheral neuropathy NCI CTCAE grade &gt;2 at the time of randomization.

          9. Patients subjected to major surgical procedures, open biopsies or those having
             significant trauma injuries within the 28 days prior to randomization, or patients who
             are expected to undergo a major surgical procedure that must necessarily be performed
             within the course of the study.

         10. Minor surgical procedures in the 7 days prior to randomization.

         11. Unsuitable bone marrow supply: ANC &lt; 1.5 x 109/L, platelets &lt; 100 x 109/L or Hb &lt; 10
             g/dL.

         12. Impaired liver function: total bilirubin total &gt; 1.5 x ULN, AST and ALT &gt; 2.5 x ULN (&gt;
             5 x ULN in patients with liver metastases).

         13. Impaired kidney function:

               1. Serum creatinine &gt; 2.0 mg/dL or 177 µmol/L.

               2. Proteinuria determined by reactive strip &gt; 2+. A 24h determination of proteins in
                  urine will be requested for the patients with &gt; 2+ in the baseline analysis and
                  must have a protein figure &lt; 1 g/24 h.

         14. Chronic treatment with oral corticoids (dose &gt; 10 mg/day of methylprednisolone or
             equivalent): the use of inhaled corticoids is allowed.

         15. Chronic treatment with acetylsalicylic acid (&gt; 325 mg/day) or clopidogrel (&gt; 75
             mg/day).

         16. Uncontrolled arterial hypertension (systolic &gt; 150 mm Hg and/or diastolic &gt; 100 mm Hg)
             or clinically significant cardiovascular disease: for example CVA (in the 6 months
             prior to randomization), coronaropathy or history of AMI in the last 6 months,
             unstable angina, congestive heart failure of grade &gt; II of the New York Heart
             Association (NYHA) or severe heart arrhythmias which are not controlled with
             medication or which can potentially interfere with the study treatment.

         17. History or evidence of hemorrhagic diathesis or coagulopathy with bleeding risk.

         18. History of abdominal fistula, gastrointestinal perforation or intra-abdominal abcess
             in the 6 months prior to randomization.

         19. Active infection requiring i.v. antibiotics at the time of randomization.

         20. Unhealed wounds, active peptic ulcer, esophageal varices.

         21. Any other disease, psychological or metabolic alteration, found in the physical or
             laboratory examination, providing reasonable indications for suspecting a disease or
             complaint for which the use of any of the study drugs are contraindicated, or which
             may affect the patient's compliance with the routine procedures of the study or which
             places the patient at a high risk of experiencing complications related to the
             treatment.

         22. Current or recent (within 30 days prior to that start of the study treatment)
             treatment with another drug under investigation or participation in another
             investigation study.

         23. Known hypersensitivity to any of the study drugs or their components.

         24. Hypersensitivity to the products of Chinese hamster ovary cells or to other human or
             humanized recombinant antibodies.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sibylle Loibl, PhD., MD.</last_name>
    <role>Study Director</role>
    <affiliation>GBG Forschungs GmbH</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Miguel Martín, PhD., MD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Clínico San Carlos</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan De la Haba, PhD., MD.</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Provincial de Córdoba</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinikum Bayreuth GmbH</name>
      <address>
        <city>Bayreuth</city>
        <zip>95445</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkoplus</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. med. W. Schoenegg</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxisklinik</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Charité</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis</name>
      <address>
        <city>Bielefeld</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evangelische Kliniken Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53113</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johanniter Krankenhaus</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis</name>
      <address>
        <city>Bremen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Praxis Dr. Glados</name>
      <address>
        <city>Coesfeld</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Johannes Hospital</name>
      <address>
        <city>Dortmund</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Berufsausübungsgemeinschaft</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Gemeinschaftspraxis</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kreiskrankenhaus Ebersberg</name>
      <address>
        <city>Ebersberg</city>
        <zip>85560</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken Esslingen</name>
      <address>
        <city>Esslingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Fulda</name>
      <address>
        <city>Fulda</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Praxis Dr. Hurtz</name>
      <address>
        <city>Halle / Saale</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albertinen-Krankenhaus</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kreiskrankenhaus Hameln</name>
      <address>
        <city>Hameln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vinzenzkrankenhaus</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universität Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxisklinik - Dialysezentrum - Herne</name>
      <address>
        <city>Herne</city>
        <zip>44623</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westpfalz-Klinikum Kaiserslautern</name>
      <address>
        <city>Kaiserslautern</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincentius Kliniken Karlsruhe</name>
      <address>
        <city>Karlsruhe</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inst. für Versorgungsforschung in der Onkologie</name>
      <address>
        <city>Koblenz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis</name>
      <address>
        <city>Kronach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Elisabeth-KKH</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Caritas Krankenhaus Lebach</name>
      <address>
        <city>Lebach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schwerpunktpraxis</name>
      <address>
        <city>Lüneburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincenz und Elisabeth-Hospital</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Mannheim</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ev. Krankenhaus Bethesda</name>
      <address>
        <city>Mönchengladbach</city>
        <zip>41061</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Neunkirchen gGmbH</name>
      <address>
        <city>Neunkirchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Nürnberg Nord</name>
      <address>
        <city>Nürnberg</city>
        <zip>90419</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frauenklinik Rheinfelden</name>
      <address>
        <city>Rheinfelden</city>
        <zip>79618</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Rosenheim</name>
      <address>
        <city>Rosenheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkolog. Schwerpunktpraxis</name>
      <address>
        <city>Rosenheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Saarbrücken</name>
      <address>
        <city>Saarbruecken</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altmark-Klinikum / Krankenhaus Salzwedel</name>
      <address>
        <city>Salzwedel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leopoldina-Krankenhaus</name>
      <address>
        <city>Schweinfurt</city>
        <zip>97421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marienkrankenhaus Schwerte</name>
      <address>
        <city>Schwerte</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxisgemeinschaft</name>
      <address>
        <city>Stade</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentralklinikum Suhl gGmbH</name>
      <address>
        <city>Suhl</city>
        <zip>98527</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Stadt Villingen-Schwenningen</name>
      <address>
        <city>Villingen-Schw.</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dres. Reichert und Janssen</name>
      <address>
        <city>Westerstede</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr.-Horst-Schmidt-Kliniken GmbH</name>
      <address>
        <city>Wiesbaden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Josefs-Hospital</name>
      <address>
        <city>Wiesbaden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marienhospital Witten</name>
      <address>
        <city>Witten</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Gemeinschaftspraxis</name>
      <address>
        <city>Wuerselen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Elche</name>
      <address>
        <city>Elche</city>
        <state>Alicante</state>
        <zip>3203</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Badalona/Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto catalán de Oncología de Barcelona</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xarxa Asistencial de Manresa</name>
      <address>
        <city>Manresa</city>
        <state>Barcelona</state>
        <zip>08243</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corporación Sanitaria Parc Taulí</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consorci Sanitari de Terrasa</name>
      <address>
        <city>Tarrasa</city>
        <state>Barcelona</state>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Mutua de Terrasa</name>
      <address>
        <city>Tarrasa</city>
        <state>Barcelona</state>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Barbastro</name>
      <address>
        <city>Barbastro</city>
        <state>Huesca</state>
        <zip>22300</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación Hospital de Alcorcón</name>
      <address>
        <city>Alcorcón</city>
        <state>Madrid</state>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>La Laguna</city>
        <state>Santa Cruz de Tenerife</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario A Coruña</name>
      <address>
        <city>A Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Oncológico de Galicia</name>
      <address>
        <city>A Coruña</city>
        <zip>15009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Provincial de Córdoba</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Jaén</name>
      <address>
        <city>Jaén</city>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Arnau de Vilanova de Lérida</name>
      <address>
        <city>Lérida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro</name>
      <address>
        <city>Madrid</city>
        <zip>28035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CIOCC Clara Campal</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Carlos Haya</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Pontevedra</name>
      <address>
        <city>Pontevedra</city>
        <zip>36001</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Salud</name>
      <address>
        <city>Toledo</city>
        <zip>45004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Valenciano de Oncología</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Arnau de Vilanova</name>
      <address>
        <city>Valencia</city>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.geicam.org</url>
  </link>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2007</study_first_submitted>
  <study_first_submitted_qc>October 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2007</study_first_posted>
  <last_update_submitted>May 18, 2015</last_update_submitted>
  <last_update_submitted_qc>May 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Fulvestrant</mesh_term>
    <mesh_term>Estradiol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

